Evotec achieves clinical development milestone as part of its multi-target alliance with Bayer
Evotec AG announced that it has reached a milestone from Bayer for the progression of a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.
This milestone was achieved under the strategic alliance between Evotec and Bayer entered in October 2012. The goal of the collaboration is to develop three clinical candidates within the five-year alliance. Both parties contribute innovative drug targets and high-quality technology infrastructures and share the responsibility for early research and pre-clinical characterisation of potential clinical candidates in the disease area of endometriosis.
Bayer will be responsible for subsequent clinical development and commercialisation while Evotec is eligible for clinical and sales milestones as well as royalties on net sales depending on the successful development and approval of a potential drug candidate.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are very pleased to report this exciting progress in our endometriosis collaboration with Bayer. The progression of this programme into clinical development is a significant achievement for the alliance. We look forward to continued success within the alliance as we strive to deliver new therapeutics for the treatment of this disease with significant unmet medical need."
Financial details were not disclosed.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Synaptic_pharmacology

New, carbon-nanotube tool for ultra-sensitive virus detection and identification

Genome sequence of the morelle decoded - Research team uses novel technologies to investigate the complex genetic material of the sour cherry variety and draw conclusions about the origin of the fruit species

"Waltzing" nanoparticles could advance search for better drug delivery methods - "Swirling and spinning" of therapeutic nanoparticles

BRAIN takes over anti-bitter patents and utility patent portfolio from BASF

Electric fungi: The biobattery that needs to be fed - Microbiology meets electrical engineering
Association between certain pain relievers and heart attack
Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug - Novel therapies could improve potency of existing AIDS treatments, help to combat drug-resistant virus strains
